Form 4 for NRIX Nurix Therapeutics, Inc.
Accepted 2022-01-04 00:00:00 ET · period of report 2022-01-03 · accession 0001209191-22-000730 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-01-04 | 2022-01-03 | NRIX | Hansen Gwenn | CSO | M - OptEx | $9.06 | +1,828 | 14.6K | +14% | +$16.6K |
| D | 2022-01-04 | 2022-01-03 | NRIX | Hansen Gwenn | CSO | S - Sale+OE | $28.96 | -1,828 | 14.2K | -11% | -$52.9K |
| DM | 2022-01-04 | 2022-01-03 | NRIX | Hansen Gwenn | CSO | M - OptEx | $0.00 | -1,828 | 67.5K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-03 | M | A | 1,428 | $9.57 | 16,025 | D | — | — | |
| 2 | Common | Common Stock | 2022-01-03 | S | D | 1,828 | $28.96 | 14,197 | D | — | — | |
| 3 | Common | Common Stock | 2022-01-03 | M | A | 400 | $7.26 | 14,597 | D | — | — | |
| 4 | Derivative | Employee Stock Option (right to buy) | 2022-01-03 | M | D | 1,428 | $0.00 | 81,905 | D | $9.57 · — to 2030-05-27 | 1,428 Common Stock | (F3) The stock option vests as to 1/48 of the total shares monthly beginning May 28, 2020 until the option is fully vested on April 28, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. |
| 5 | Derivative | Employee Stock Option (right to buy) | 2022-01-03 | M | D | 400 | $0.00 | 67,466 | D | $7.26 · — to 2030-02-26 | 400 Common Stock | (F2) The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. |